Biologic survival

Journal of Drugs in Dermatology

Volumn 8, Issue 4, 2009, Pages 329-333

  Noiles, Kristin ^a   Vender, Ronald ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIPSORIASIS AGENT; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; USTEKINUMAB; BIOLOGICAL PRODUCT; DERMATOLOGICAL AGENT; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; BIOLOGICAL THERAPY; DRUG EFFICACY; HUMAN; MONOTHERAPY; PATIENT COMPLIANCE; PSORIASIS; PSORIASIS SEVERITY INDEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; UNSPECIFIED SIDE EFFECT; REVIEW;

ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; DERMATOLOGIC AGENTS; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS;

EID: 79955483598     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598-606. (Pubitemid 44436647)
2. Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974;148(1):1-18.
3. Gottlieb AB, Hamilton T, Caro I, et al. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trial. J Am Acad Dermatol. 2006;54(4 Suppl 1):S154-163. (Pubitemid 43238298)
4. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106-115. (Pubitemid 350298146)
5. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient- membership survey. Arch Dermatol. 2001;137(3):280-284. (Pubitemid 32240779)
6. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol Symp Proc. 2004;9(2):136-139. (Pubitemid 38457271)
7. Christophers E, Griffiths CE, Gaitanis G, et al. The unmet treatment need for moderate to severe psoriasis: Results of a survery and chart review. J Eur Acad Dermatol Venereol. 2006;20(8):921-925.
8. Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005;141:31-38. (Pubitemid 40144437)
9. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted Tcell modulator, efalizumab for plaque psoriasis. N Eng J Med. 2003;349:2004-2013. (Pubitemid 37448923)
10. Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol. 2005;52:425-433.
11. Hamilton T, Menter A, Caro I, et al. Safety of efalizumab therapy in patients with moderate to severe psoriasis: An open-label extension of a phase IIIb trial. Drug Safety. 2008;31(8):715-726. (Pubitemid 352019569)
12. Papp KA, Bressnick R, Fretzin S, et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol. 2006; 45(5):605-614.
13. Leonardi C, Menter A, Hamilton T, et al. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol. 2008;158:1107-1116. (Pubitemid 351521472)
14. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-1312. (Pubitemid 40933433)
15. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627-1632. (Pubitemid 37523083)
16. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56:598-603. (Pubitemid 46400183)
17. Van de Kerkhof PCM, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerate in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol. 2008; 159:1177-1185.
18. Tyring S, Gordon KB, Langley RG, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dematol. 2007;143: 719-726. (Pubitemid 46955730)
19. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106-115. (Pubitemid 350298146)
20. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006; 55:598-606. (Pubitemid 44436647)
21. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534-541.
22. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005; 366(9494):1367-1374. (Pubitemid 41443403)
23. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. Intermittent inflixmab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:31.e1-31.e15.
24. Krueger GG, Papp KA, Stough DB, et al. A randomized, doubleblind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47:821-833. (Pubitemid 35403039)
25. Lebwohl M, Christophers E, Langely R, et al. An international, randomized, double-blind, placebo-controlled phase III trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dematol. 2003;139:719-727. (Pubitemid 36705938)
26. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monocloncal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008; 371:1665-1674. (Pubitemid 351671883)
27. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibod, in patients with psoriasis : 52 week results from a randomised, double blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-1684. (Pubitemid 351671884)
28. Brimhall AK, King LN, Licciardone H, et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159(2):274-285. (Pubitemid 352009861)